AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity
Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...
BBC14h
Market Data
© 2024 BBC. The BBC is not responsible for the content of external sites. Read about our approach to external linking.
BBC13h
Market Data
From the end of November Market data will no longer be displayed here. As of 3:25 13 Nov 2024 15 min delay Source: Morningstar © 2024 BBC. The BBC is not responsible ...